Effect of itraconazole on the pharmacokinetics of midazolam in bactrian camels Yue Weidong1, San Ren1, Hasi Surong1,2 1College of Veterinary Medicine, Inner Mongolia Agricultural University, Key Laboratory of Clinical Diagnosis and Treatment Technology in Animal Disease, Ministry of Agriculture and Rural Affairs, Hohhot, 010018 2Inner Mongolia Institute of Camel Research, Badain Jaran, 750300, China email: baohaas@163.com
Online published on 30 January, 2020. Abstract The objective of this study was to investigate the effect of the CYP3A enzyme specific inhibitor Itraconazole on the pharmacokinetics of midazolam in Bactrian camels. The camels were allocated randomly into 2 groups of 5 animal each. Camels in group 1 were given a single dose of midazolam only, and camels in group 2 were administered 4 consecutive days of Itraconazole and a single dose of Midazolam. Blood samples were collected from the jugular vein at different times. Midazolam concentration in plasma was determined by high-performance liquid chromatography-ultraviolet detection. The pharmacokinetic parameters of Midazolam were analysed by Phoenix WinNonLin v7.0. There were no significant differences in the clearance or mean residence time of midazolam between the two groups. However, substantial differences were observed in T½, Tmax, Cmax, AUC0-t and Vd between them. T½, Cmax and AUC0-t in group 2 were higher than that in group 1, whereas Tmax and Vd in group 2 were significantly lower than that in group 1. Therefore, midazolam was metabolised mainly by CYP3A in Bactrian camels, and Itraconazole, a specific inhibitor of CYP3A enzyme, could inhibit CYP3A activity significantly and affect the pharmacokinetics of midazolam in Bactrian camels. Top Keywords Bactrian camel, CYP3A enzyme, itraconazole, midazolam, pharmacokinetics. Top |